Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases.
{"title":"Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases.","authors":"Makoto Ishitobi, Atsushi Yoshida, Yuri Kimura, Yasuaki Sagara, Yuka Ono, Koji Takada, Yuko Takahashi, Takahiro Tsukioki, Mao Kimoto, Tomo Osako, Takehiko Sakai","doi":"10.1007/s12282-025-01732-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is no consensus regarding the optimal margin status among patients with breast cancer treated with neoadjuvant chemotherapy (NAC), breast-conserving surgery, and radiotherapy (breast-conserving treatment [BCT]).</p><p><strong>Methods: </strong>In total, 1813 patients with newly diagnosed stage 1-3 breast cancer who underwent BCT after NAC were evaluated to determine the impact of margin status on ipsilateral breast tumor recurrence (IBTR).</p><p><strong>Results: </strong>During a median follow-up period of 8.0 years (range 0.1-17.0 years), the 8-year IBTR-free survival rate was 95.9%. Patients with positive margins had significantly worse IBTR-free survival than those with negative margins (8-year IBTR-free survival rate: 87.6% vs. 96.2%, p = 0.010). Multivariate analysis showed that margin status was significantly associated with IBTR-free survival (hazard ratio: 3.1; 95% confidence interval 1.3-7.2; p = 0.0081).</p><p><strong>Conclusions: </strong>This multicenter retrospective study demonstrated that margin status is significantly associated with IBTR-free survival in patients who received NAC and BCT, consistent with findings in upfront-surgery cases.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1044-1051"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast cancer (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12282-025-01732-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is no consensus regarding the optimal margin status among patients with breast cancer treated with neoadjuvant chemotherapy (NAC), breast-conserving surgery, and radiotherapy (breast-conserving treatment [BCT]).
Methods: In total, 1813 patients with newly diagnosed stage 1-3 breast cancer who underwent BCT after NAC were evaluated to determine the impact of margin status on ipsilateral breast tumor recurrence (IBTR).
Results: During a median follow-up period of 8.0 years (range 0.1-17.0 years), the 8-year IBTR-free survival rate was 95.9%. Patients with positive margins had significantly worse IBTR-free survival than those with negative margins (8-year IBTR-free survival rate: 87.6% vs. 96.2%, p = 0.010). Multivariate analysis showed that margin status was significantly associated with IBTR-free survival (hazard ratio: 3.1; 95% confidence interval 1.3-7.2; p = 0.0081).
Conclusions: This multicenter retrospective study demonstrated that margin status is significantly associated with IBTR-free survival in patients who received NAC and BCT, consistent with findings in upfront-surgery cases.